---
title: "PeRsOnalising Treatment Of Diabetic Nephropathy:"
nct_id: NCT03509454
overall_status: COMPLETED
sponsor: Peter Rossing
study_type: OBSERVATIONAL
primary_condition: Diabetes Mellitus, Type 1
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03509454.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03509454"
ct_last_update_post_date: 2018-04-26
last_seen_at: "2026-05-12T06:21:16.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# PeRsOnalising Treatment Of Diabetic Nephropathy:

**Official Title:** PeRsOnalising Treatment Of Diabetic Nephropathy: From Albuminuria to Multidimensional Characterisation of Diabetic Nephropathy - a Cross-sectional Study

**NCT ID:** [NCT03509454](https://clinicaltrials.gov/study/NCT03509454)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 210
- **Lead Sponsor:** Peter Rossing
- **Conditions:** Diabetes Mellitus, Type 1, Diabetes Complications, Diabetic Nephropathies
- **Start Date:** 2016-04-01
- **Completion Date:** 2018-04-01
- **CT.gov Last Update:** 2018-04-26

## Brief Summary

Background: Today diabetic nephropathy is a frequent, and the most lethal and costly complication of diabetes. Although treating blood pressure with agents blocking renin angiotensin system has improved outcome, the prognosis is still poor and no new interventions have been successful during the past decade. There is an urgent need for discovery of new pathways behind the development and progression of diabetic nephropathy as well as of biomarkers which can identify subjects at risk of developing adverse events. Objective: By using a multidimensional 'omics' approach, we aim to search for novel proteins, metabolites and pathways that will point to the putative new mechanisms which underlie the early renal decline.

Design: Cross-sectional study, with long-term register-based follow-up. Study population: 160 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen stratified based on stage of diabetic kidney disease, and 50 healthy non-diabetic controls. Endpoints: Primary endpoint: Glycocalyx thickness, assessed as perfused boundary region. Secondary endpoints: Gut microbiome characterisation and markers of gastrointestinal inflammation, autonomic and periphery neuropathy, urine and plasma Flow Cytometry Analysis (FACS), metabolomics and proteomics in plasma and urine, and other potential biomarkers.

## Detailed Description

Design: Cross-sectional study, with long-term register-based follow-up. Study population: 160 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen stratified based on stage of diabetic kidney disease, and 50 healthy non-diabetic controls. Endpoints: Primary endpoint: Glycocalyx thickness, assessed as perfused boundary region. Secondary endpoints: Gut microbiome characterisation and markers of gastrointestinal inflammation, autonomic and periphery neuropathy, urine and plasma Flow Cytometry Analysis (FACS), metabolomics and proteomics in plasma and urine, and other potential biomarkers.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Patients with type 1 diabetes
* Written informed consent must be provided before participation
* Male or female patients \>18 years of age with a diagnosis of type 1 diabetes (WHO criteria)
* Persistent urinary albumin creatinine ratio (UACR) assessed from EPJ (Electronic Patient Journal):
* \< 30 mg/g in 2 out of 3 consecutive samples (normoalbuminuria)
* 30 - 299 mg/g in 2 out of 3 consecutive samples (microalbuminuria)
* ≥ 300 mg/g in 2 out of 3 consecutive samples (macroalbuminuria) - at least 30 with concurrent eGFR \< 60 ml/min/1.73m2

  2\. Control subjects without diabetes
* Written informed consent must be provided before participation.
* Male or female patients \>18 years of age without a diagnosis of diabetes (assessed by Hb1Ac, haemoglobin and creatinine)

Exclusion Criteria: (Both subjects with and without diabetes)

* Non-diabetic kidney disease as indicated by medical history and/or laboratory findings
* Renal failure (eGFR\<15 ml/min/1.73m2), dialysis or kidney transplantation
* Change in RAAS blocking treatment during the last month
* Treatment with antibiotics during the last 2 month
* Pregnancy or breastfeeding (urine HCG is performed on all fertile women)
* Patients who, in the judgement of the investigator, is incapable to participate
* For controls: Other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion
```

## Arms

- **Type 1 DM, Normo albuminuric** — Type 1 diabetics with no history of albumnuria (UACR \< 30 mg/g in 2 out of 3 consecutive samples)
- **Type 1 DM, Micro albuminuric** — Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
- **Type 1 DM, Macro albuminuric** — Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
- **Healthy subjects** — Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.

## Primary Outcomes

- **The microvascular function by estimating the glycocalyx thickness** _(time frame: 2019)_ — Glycocalyx thickness assessed as perfused boundary region by a hand-hold camera (GlycoCheck)

## Secondary Outcomes

- **Gut microbiome** _(time frame: 2019)_
- **Urine and plasma Flow Cytometry Analysis (FACS)** _(time frame: 2019)_
- **Metabolomics in plasma** _(time frame: 2019)_
- **Metabolomics in urine** _(time frame: 2019)_
- **proteomics in urine** _(time frame: 2019)_
- **proteomics in plasma** _(time frame: 2019)_
- **Autonomic neuropathy** _(time frame: 2019)_
- **peripheral neuropathy** _(time frame: 2019)_

## Locations (1)

- Steno Diabetes Center, Gentofte Municipality, Copenhagen, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.steno diabetes center|gentofte municipality|copenhagen|denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03509454.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03509454*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*